Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sergio Traversa
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 0.45
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 13.68
Financials
Net Income
$-12.91MEBITDA
$-12.91MFree Cash Flow
$-9.61MEPS (diluted)
$-0.11Shares Outstanding (diluted)
112.38M+3634.7%Operating Expenses
$15.01MCash & Debt
$217.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-57.39M | $-1.45 |
| 2024 | $0.00 | $-79.98M | $-2.65 |
| 2023 | $0.00 | $-98.79M | $-3.28 |
| 2022 | $0.00 | $-157.04M | $-5.30 |
| 2021 | $0.00 | $-125.75M | $-7.16 |
| 2020 | $0.00 | $-59.46M | $-3.81 |
| 2019 | $0.00 | $-15.01M | $-1.63 |
| 2018 | $0.00 | $-17.32M | $-2.74 |
| 2017 | $0.00 | $-8.96M | $-2.86 |
| 2016 | $0.00 | $-6.29M | $-2.08 |
| 2015 | $0.00 | $-2.98M | $-1.03 |
| 2014 | $0.00 | $-20.80M | $-8.37 |
| 2013 | $5.1K | $-45.0K | $-0.03 |
| 2012 | $7.9K | $-12.1K | $-0.01 |
Valuation
RLMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-4.76%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·35d ago·Neutral
…eutics to Participate at the Wells Fargo 21st Annual Healthcare Conference CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 1…
View source ↗ - Newszacks.com·35d ago·Negative
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·55d ago·Neutral
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise -22.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.20beat
- Tue, May 12$-0.22 vs $-0.18miss
- Thu, Mar 19$-0.27 vs $-0.14miss
- Thu, Nov 13$-0.30 vs $-0.04miss
- Thu, Aug 7$-0.30 vs $-0.25miss
- Mon, May 12$-0.58 vs $-0.31miss
Estimates and results for RLMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RLMD officers and directors.
- Bought
- $6.0m
- Sold
- —
39 trades
0 trades
- Shenouda Magedbought
- Traversa Sergiobought
- Shenouda Magedbought
- Traversa Sergiobought
- Traversa Sergiobought
- Shenouda Magedbought
- Shenouda Magedbought
- Ence Chuckbought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.